Agenus Secures $20M Payment for BOT+BAL Manufacturing Collaboration
Agenus has triggered a $20 million contingent payment under its collaboration with Zydus Life Sciences for CMC and production activities supporting botensilimab and balstilimab manufacturing. The funding will underpin commercial supply initiation, regulatory readiness for BLA/MAA submissions and inventory build-up for clinical trials and access programs.
1. Contingent Payment Triggered
Agenus has triggered a $20 million contingent payment under its strategic collaboration with Zydus Life Sciences following contracted CMC and production work orders for botensilimab and balstilimab. These funds are designated for manufacturing activities supporting commercial supply initiation and regulatory submissions.
2. Manufacturing and Regulatory Readiness
The manufacturing activities include CMC processes to meet BLA and MAA requirements and to build inventory for the BATTMAN Phase 3 trial, French AAC program, and named patient programs. This ensures scalability of BOT+BAL supply without additional capital expenditures affecting cash position.
3. Collaboration Framework and Future Milestones
Under the agreement, up to $50 million in contingent payments can be triggered by production orders, with the remaining $30 million allocated for future manufacturing needs. The partnership, closed in January 2026, secures long-term U.S. biologics capacity for global development and potential commercialization of BOT+BAL.